Unide the Paperwork Reduction Act of 1995.		U.S. Patent and Tra-	PTO/SB/21 (05-03) pproved for use through 04/30/2003. OMB 0651-0031 demark Office; U.S. DEPARTMENT OF COMMERCE mation unless it displays a valid OMB control number.
Under the Paperwork Reduction Act of 1995.	Application Number		
TRANSMITTAL	Filing Date		uary 11, 2004
FORM	First Named Inver		g H. Lee, et al.
(to be used for all correspondence after initial f	ing) Art Unit	1625	<u> </u>
	Examiner Name	not a	vailable yet
Total Number of Pages in This Submission	Attorney Docket N		
	ENCLOSURES (C	heck all that apply)	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Pa Petition Petition to Convert to Provisional Application Power of Attorney, Rochange of Correspoor Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks	o a on evocation ndence Address	After Allowance communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter Other Enclosure(s) (please Identify below):  A return-receipt postcard is enclosed.  References
SIGNA	URE OF APPLICANT,	ATTORNEY, OF	RAGENT
Signature 1. II C	Company, John H. Eng	elmann (28,075)	
CI	RTIFICATE OF TRAN	SMISSION/MAIL	LING
			ted with the United States Postal Service with O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name  Julie K. Lyons			
Signature Juli. E K.	Lyons		Date May 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			Atty. Docket No. 01453.US1			Serial No. 10/776,837						
0 1 2004	<b>3</b>			Applicants Byung H. Lee, et al.								
MAY 0 7 2004 E				Filing Date 2/11/200	1625							
Te IRADEL			U.S. PA	TENT DOCUMENTS			<u> </u>		-			
Examiner Initial		Document Number	Date	Name		Class	Subclass		Filing Date If Appropriate			
	AA	5,498,720	March 12, 1996	96 Lee		546	276					
	AB	5,489,598	Feb. 6, 1996	Connor et al.		514	384					
	AC	4,481,360	Nov. 6, 1984 Gall et al.			546 210						
			FOREIGN PA	ATENT DOCUMENTS								
		Document	Date	Country	Clas	s S	ubclass	Tr	anslation			
		Number	·	·	,	•	• • • • • • • • • • • • • • • • • • • •		Yes	No		
	AD	WO 01/31005	May 3, 2001	WIPO	C12	N 1	5/12					
,		(	OTHER PRIOR ART (Inc	cluding Author, Title, Date, Pertine	ent Page	es, Etc.)						
	AI			Kiev 252017 pp. 914-917. op. 1132-1134, August 1977						976.		
	АJ	Berge et al., J. Miami. Sci., 66:1-19 (1977)										
	AK	Birgul et al., The EMBO J., 18 5892-5900 (1999)										
	AL	N. Bodor, "Novel Approaches in Prodrug Design," Drugs of the Future, 6(3):165-182 (1981)										
	AM	J. W. Bowman, et al., J. of Neurophys., 74(5), 1880-1888 (1995)										
-	AN	H. Bundgaard, "Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemica Entities," in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, N.Y. (1985)										
	AO R. E. Davis, et al., J. of Neurosci., 9(2), 403-414 (1989)											
	AP N. N. Gulermann, et al., Il Farmaco 56(12), 953-958 (2001)											
	AQ											
	AR											
	AS	Lee, op.cit. E. G. Knish, et al., Farmatsevtichnii Zhurnal 2, 64-65 (1983) and translation, "Synthesis, Properties and Biological activity of 5-Acylalykymercapto-1,2, 4-Triazoles" Zaporozhe Medical Institute (UDC)										
	АТ	Lenz et al., Biochem. Biophys. Res. Comm. 273, 1126-1131 (2000)  R. Nichols, J. Neurogenetics, 16, 1-28 (2002)										
	AU											
	AV	R.E. Notari, "The	eory and Practice of Pro	drug Kinetics," Methods in	Enzyn	nology	, 112:309	-323	(1985)			
Examiner				Date Considered			-					